Brace Pharma has invested $15m in cancer drug developer Tyrogenex, which will use the funding to advance its lead product.
Tyrogenex, a US-based biotechnology company working to develop treatments for specific cancers, has closed a $15m series D funding round with investment from Brace Pharma, the investment arm of EMS, a Brazil-based pharmaceutical company.
The funding from this investment round will be used to move towards clinical trials of X-82, an orally administered drug that aims to treat solid cancers and various eye diseases.
Sheridan G Snyder, chairman and chief executive of Tyrogenex, said: “This significant investment from…
